REVANCE THERAPEUTICS, INC.
BiotechREVANCE THERAPEUTICS, INC. is a biotechnology company focused on Immunology, Dermatology.
FDA Novel Drug Designations
(2022)See 1 novel approval →
REVANCE THERAPEUTICS, INC. at a Glance
- Strong track record with 92% execution quality across 28 trials
- Fast trial execution (10 months median completion)
REVANCE THERAPEUTICS, INC.'s Key Drugs
REVANCE THERAPEUTICS, INC.'s core commercial portfolio centers on DAXXIFY, spanning Immunology and Dermatology — its most strategically important drugs approved in the last 15 years.
REVANCE THERAPEUTICS, INC.'s Recent FDA Approvals
New NDA/BLA approvals for REVANCE THERAPEUTICS, INC. over the last two years — novel drugs only, excluding generics and label supplements.
REVANCE THERAPEUTICS, INC.'s Therapeutic Areas
REVANCE THERAPEUTICS, INC.'s approved drugs and pipeline span 2 therapeutic areas, led by Immunology and Dermatology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
REVANCE THERAPEUTICS, INC.'s Top Competitors
REVANCE THERAPEUTICS, INC.'s closest competitors by therapeutic-area and drug-target overlap include Pfizer, Eli Lilly, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
REVANCE THERAPEUTICS, INC. Pipeline Snapshot
REVANCE THERAPEUTICS, INC. has 19 active clinical programs from ClinicalTrials.gov — 10 Phase 3, 9 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • DAXXIFY leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 7/8 completed
- • Speed: 10 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2022-09-07
- Latest
- 2023-08-11
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges